Immune related adverse events and treatment discontinuation in patients older and younger than 75 years with advanced melanoma receiving nivolumab or pembrolizumab-Reference-Cited by-同舟云学术

Immune related adverse events and treatment discontinuation in patients older and younger than 75 years with advanced melanoma receiving nivolumab or pembrolizumab

Published:2021-10 Issue: Volume: Page:
ISSN:1879-4068
Container-title:Journal of Geriatric Oncology
language:en
Short-container-title:Journal of Geriatric Oncology

Author:

Ksienski Doran,Truong Pauline T.,Croteau Nicole S.,Chan Angela,Sonke Eric,Patterson Tiffany,Clarkson Melissa,Hackett Samuel,Lesperance Mary

Funder

AstraZeneca Canada Inc

Publisher

Elsevier BV

Subject

Geriatrics and Gerontology,Oncology

Reference36 articles.

1. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials;Korn;J Clin Oncol,2008

2. Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings;Kummerow Browman;Expert Opin Drug Saf,2019

3. The blockade of immune checkpoints in cancer immunotherapy;Pardoll;Nat Rev Cancer,2012

4. Pembrolizumab versus ipilimumab in advanced melanoma;Robert;N Engl J Med,2015

5. Nivolumab in previously untreated melanoma without BRAF mutation;Robert;N Engl J Med,2015

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The relationship between LDH and GLIM criteria for cancer cachexia: Systematic review and meta-analysis;Critical Reviews in Oncology/Hematology;2024-07

3. Unusual encephalopathy with Wernicke–Korsakoff syndrome-like features due to adjuvant nivolumab for malignant melanoma;Journal of Oncology Pharmacy Practice;2023-11-19

4. Tolérance et efficacité des inhibiteurs de points de contrôle immunitaire en monothérapie chez les patients âgés;Bulletin du Cancer;2023-11

5. Predicting immune‐related adverse events using a simplified frailty score in cancer patients treated with checkpoint inhibitors: A retrospective cohort study;Cancer Medicine;2023-05-03